Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma

Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma

Abstract Background Precision medicine calls for an early indicator of treatment efficiency. Circulating tumor DNA (ctDNA) is a promising marker in this setting. Our prospective study explored the association between disease development and change of ctDNA during first line chemotherapy in patients...

Full description

Bibliographic Details
Main Authors: C. B. Thomsen, T. F. Hansen, R. F. Andersen, J. Lindebjerg, L. H. Jensen, A. Jakobsen
Format: Article
Language:English
Published: BMC 2018-03-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Circulating tumor DNA
RAS/RAF mutations
Metastatic colorectal cancer
Liquid biopsy
Monitoring
Treatment efficiency
Online Access:http://link.springer.com/article/10.1186/s13046-018-0723-5

Internet

http://link.springer.com/article/10.1186/s13046-018-0723-5

Similar Items